Adverse Hepatic Effects Associated with Administration of Antiretroviral Drugs (Nevirapine, Lamivudine and Stavudine) to Albino Rats: Implication for Management of Patients with HIV/AIDS

1R. A. Umar, 1S.W. Hassan, 1M.J. Ladan, 1I.K. Matazu, 2B. Shehu, 1R.A. Shehu, 1L.G. Muhammed and 1F.I. Molabo
1Department of Biochemistry, Usmanu Danfodiyo University, P.M.B. 2346, Sokoto, Nigeria
2Laboratory Services Unit, Health Services Management Board, Sokoto, Nigeria
3Veterinary Public Health Laboratory, Department of Veterinary Microbiology and Public Health, Faculty of Veterinary Medicine, Usmanu Danfodiyo University, P.M.B. 2346, Sokoto, Nigeria

Abstract: We studied the effects of acute and sub-chronic oral administration of nevirapine, lamivudine and stavudine on liver function in albino rats. Acute administration of nevirapine resulted in significant (p<0.05) increases in activities of Aspartate amino transferase (AST) and Alanine amino transferase (ALT). Total proteins, albumin and globulin were significantly lowered. Upon sub-chronic administration of nevirapine, only AST and ALT activities were significantly raised. Acute administration of lamivudine was associated with significantly (p<0.05) lower albumin and globulin and higher total bilirubin and conjugated bilirubin levels. There were no significant differences (p>0.05) in liver function profiles associated with sub-chronic administration of the drug. However, acute and sub-chronic administrations of stavudine were not associated with significant (p>0.05) changes in liver function profiles. We conclude that while the use of stavudine is safe, acute and sub-chronic oral administration of nevirapine and lamivudine are associated with hepatotoxicity and hepatoprotective agents should be incorporated in the treatment regimens employing these drugs to avert life-threatening complications.

Key words: Adverse hepatic effects, administration, antiretroviral drugs, hepatotoxicity, HIV/AIDS management, albino rats

INTRODUCTION

Since the first report of cases of Acquired Immune Deficiency Syndrome (AIDS) by Gottlieb et al. (1981) in the USA and with 800,000 new infections occurring daily (Goulder and Watkins, 2004) the disease has become a global pandemic. By the year 2006, AIDS had infected more than 65 million people out of which 25 million have died (Fauci, 2006). Of the people infected with the disease, 44.2 million (68%) are in Sub-Saharan Africa, making it the region with the highest overall AIDS prevalence rate in the general adult (15-49 years) population (WHO, 2005). In Nigeria, the acclaimed heart beat of Africa, the prevalence of HIV infection has been increasing steadily; from 1.8% in 1991 to 3.8% in 1993, 4.5% in 1996, 5.4% in 1999 and 5.8% in 2001 (Anonymous, 2001). Until recently (with the advent of antiretroviral therapy) HIV infection was a death sentence, in most parts of the world it still is (Goulder and Watkins, 2004) due to non-availability of the anti AIDS drugs.
ignorance, financial incapacity or other factors. The introduction of Highly Active Antiretroviral Therapy (HAART), a cocktail of nucleoside and non-nucleoside analogues capable of inhibiting reverse transcriptase and proteases, in industrialized countries during the mid-1990s led to well documented reductions in the risk of AIDS-defining illness and AIDS related mortality (Anonymous, 2003).

The deployment of antiretroviral drugs within the concept of HAART for the treatment of HIV/AIDS revolutionized the management of the disease by suppressing viral loads to non-detectable levels, improving immune status and reducing the incidence of opportunistic infections, resulting in a dramatically improved clinical course and survival in infected patients (Anonymous, 2003). With AIDS becoming a global emergency, antiretroviral drugs became the most effective health care intervention (Anonymous, 2003). In line with its mandate, the WHO has committed itself to the 3-by-5 target for anti-retroviral therapy which aims to ensure that 3 million HIV-infected people in developing countries have access to anti-retroviral therapy by the end of 2005 (Haines, 2003). This measure, by making anti-retroviral drugs available to people living with HIV/AIDS, will go a long way in preventing transmission of the disease and improving the quality of life of the victims.

However, increasing reports of adverse clinical events and toxicities have diminished the enthusiasm generated by HAART. Some of the clinical events include AIDS-related insulin resistance, lipodystrophy syndrome, gastrointestinal symptoms, hyperglycaemia (Schambelan et al., 2002; Anonymous, 2003). The most common and troublesome toxicities of nucleoside transcriptase analogues are notably hepatotoxicity (Schambelan et al., 2002), anaemia and neutropenia (Fiselle et al., 1990), hepatic steatosis and osteonecrosis (Schambelan et al., 2002). These reports coupled with limited knowledge of HAART have generated confusion and loss of confidence amongst the population in Africa which militate against the acceptance and compliance to these drugs (Anderson, 2005; Gebrekristos et al., 2005). For example, in Durban, South Africa, of the women attending an AIDS clinic about 50% are HIV positive but none receives antiretroviral therapy (Gould, 2006).

African studies on the safety of these drugs are few. In an earlier communication (Umar et al., 2007) we have reported the effect of administration of some antiretroviral drugs on haematological profiles. In the present preliminary report, we assessed the safety of the use of antiretroviral drugs (nevirapine, lamivudine and stavudine) based on the effects on liver function profiles in albino rats.

**MATERIALS AND METHODS**

**Drugs and Source**

The three antiretroviral drugs used for the study were obtained from the Pharmacy, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria. The drugs were produced for Evans Medical Plc. Nigeria by Cipla Limited, Verma Goa, India, with National Agency for Food Drug Administration and Control (NAFDAC) reg. No. 04-6335, 04-6232 and 04-6334 for Stavudine®, Lamivudine® and Nevirapine®, respectively.

**Reagents**

All reagent kits used in the study were obtained from Randox Laboratories, U.K.

**Animals and Treatment**

Thirty male albino rats (Wistar Strains) weighing 200-269 g were obtained from Veterinary Research Institute Vom, Jos, Plateau state, Nigeria. The animals were housed singly in clean cages and fed on chicken mash (Bendel Foods Ltd., Nigeria) for 2 weeks to acclimatize prior to the experiment. They were subsequently weighed and randomly assigned into four treatment and control groups (5 groups of 6 rats each). For treatment groups, each subgroup was labelled to represent the drugs to
be administered. In humans (adults) the therapeutic doses of the drugs were 200, 600 and 350-400 mg
daily for stavudine, lamivudine nevirapine, respectively. To create a rat model for the study we
assumed an average human being weight 70 kg and calculated the corresponding therapeutic doses for
the rat models. The drugs and dosages were as follows: stavudine® 0.57, lamivudine® 2.06 and
nevirapine® 1.54 mg kg⁻¹ body weights orally, daily for 1 and 4 weeks, respectively to represent acute
and sub-chronic dosing. This enabled us to study the effects of the drugs in short (1 week) and medium
(4 weeks) terms. The control group was given 0.9% normal saline as placebo. At the end of one and
4 weeks, the animals were sacrificed painlessly under chloroform anesthesia. Blood samples (1 mL)
were collected in vacutainer tubes and allowed to clot for 30 min before it was centrifuged for 10 min
at 3000 rpm to obtain sera for the analyses.

Liver Function Tests
Aspartate and alanine amino transferase activities were assayed according to the method of
Reitman and Frankel (1957), total proteins were determined by Bluret method of Whicher et al. (1994)
using Bluret reagent of King (1951), albumin was determined using bromocresol green binding method,
globulin was obtained by subtracting the albumin value from the total protein, total and direct bilirubin
were determined as described by Perry et al. (1983).

Statistical Analysis
Statistical analysis was performed using Graph pad Instat version 3.02 (San Diego, USA). The
data were described using descriptive statistics and analysis of variance (Bonferroni compare all
columns) was used to test for the level of significance between means. A p-value of <0.05 was
considered statistically significant.

RESULTS
The effect of acute and sub-chronic administrations of stavudine®, lamivudine and nevirapine®
on liver functions in rats are presented in Table 1 and 2.

Stavudine
Acute and sub-chronic administrations of stavudine did not produce significant (p>0.05) changes
in liver function profiles.

Lamivudine
Acute administration was associated with significantly (p<0.05) lower globulin and albumin levels
and raised total bilirubin and conjugated bilirubin levels. Total proteins were non significantly raised.
There were no significant differences (p>0.05) in liver functions parameters with sub-chronic
administration of the drug.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control</th>
<th>Stavudine</th>
<th>Lamivudine</th>
<th>Nevirapine</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASAT (UL⁻¹)</td>
<td>30.7±0.50</td>
<td>32.7±4.03</td>
<td>31.5±4.42</td>
<td>36.5±4.04*</td>
</tr>
<tr>
<td>ALAT (UL⁻¹)</td>
<td>17.2±4.50</td>
<td>19.7±2.36</td>
<td>18.5±1.29</td>
<td>21.2±5.20*</td>
</tr>
<tr>
<td>T. proteins (g DL⁻¹)</td>
<td>4.4±0.62</td>
<td>3.3±0.80</td>
<td>3.2±0.90</td>
<td>3.0±0.35*</td>
</tr>
<tr>
<td>Albumin (g DL⁻¹)</td>
<td>3.6±0.70</td>
<td>2.4±0.70</td>
<td>2.6±0.94</td>
<td>2.5±0.31*</td>
</tr>
<tr>
<td>Globulin (g DL⁻¹)</td>
<td>0.7±0.10</td>
<td>0.8±0.47</td>
<td>0.9±0.05*</td>
<td>0.9±0.10*</td>
</tr>
<tr>
<td>T. bilirubin (mg DL⁻¹)</td>
<td>0.2±0.05</td>
<td>0.3±0.09</td>
<td>0.6±0.18*</td>
<td>0.4±0.10*</td>
</tr>
<tr>
<td>D. bilirubin (mg DL⁻¹)</td>
<td>0.1±0.02</td>
<td>0.1±0.02</td>
<td>0.3±0.07*</td>
<td>0.1±0.08</td>
</tr>
</tbody>
</table>

Values are Mean±SD, * Indicates significant difference (p<0.05), ASAT = Aspartate amino transferase, ALAT = Alanine
amino transferase, T = Total, D = Direct, UL⁻¹ = Units per liter.
Table 2: Effect of sub-chronic administration of stavudine, lamivudine and nevirapine on liver functions in rats

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control (UL)</th>
<th>Stavudine (UL)</th>
<th>Lamivudine (UL)</th>
<th>Nevirapine (UL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASAT (UL)</td>
<td>84.5±7.94</td>
<td>87.75±8.02</td>
<td>95.75±10.24</td>
<td>118.3±15.99*</td>
</tr>
<tr>
<td>ALAT (UL)</td>
<td>33.0±4.35</td>
<td>35.75±9.22</td>
<td>31.0±1.1</td>
<td>42.7±3.86*</td>
</tr>
<tr>
<td>T. Proteins (g dl⁻¹)</td>
<td>4.1±0.64</td>
<td>4.22±0.15</td>
<td>3.68±0.35</td>
<td>3.85±0.28</td>
</tr>
<tr>
<td>Albumin (g dl⁻¹)</td>
<td>3.4±0.49</td>
<td>3.60±0.12</td>
<td>3.10±0.29</td>
<td>3.25±0.24</td>
</tr>
<tr>
<td>Globulin (g dl⁻¹)</td>
<td>0.68±0.15</td>
<td>0.63±0.05</td>
<td>0.50±0.14</td>
<td>0.58±0.05</td>
</tr>
<tr>
<td>T. bil. (mg dl⁻¹)</td>
<td>0.75±0.02</td>
<td>0.78±0.10</td>
<td>0.79±0.05</td>
<td>0.74±0.01</td>
</tr>
<tr>
<td>D. bil. (mg dl⁻¹)</td>
<td>0.13±0.01</td>
<td>0.16±0.10</td>
<td>0.14±0.01</td>
<td>0.15±0.02</td>
</tr>
</tbody>
</table>

Values are means±SD. * indicates significant difference (p<0.05). ASAT = Aspartate amino transferase, ALAT = Alanine amino transferase, T = Total, T. bil. = Total bilirubin, D. bil. = Direct bilirubin, UL⁻¹ = Units per liter

Nevirapine

At acute administration Nevirapine resulted in significant (p<0.05) increases in activities of aspartate amino transferase (AST) and alanine amino transferase (ALT). Total proteins, albumin and globulin were significantly lowered. Upon sub-chronic administration of Nevirapine, only AST and ALT activities were still significantly raised. Total proteins, albumin and globulin levels improved, while levels of total and direct bilirubin were almost similar to the controls.

DISCUSSION

In the face of the global AIDS pandemic advancement in the treatment of the disease has been strikingly impressive, for example patients on antiretroviral therapy now live at least 13-14 years longer than those without the therapy (Walensky, 2006). But problems still remain. Hepatotoxicity has arisen as a major side effect of antiretroviral drugs limiting their use in treatment regimens. Severe hepatic reactions attributed to nevirapine as part of HAART or in post-exposure prophylaxis regimens have been reported (Anonymous, 2000; Johnson and Baraboutis, 2000; Martinez et al., 2001). Hepatotoxicity has been reported for all antiretroviral classes and nevirapine was attributed the highest risk (Sulkowski et al., 2000; Reisler et al., 2001). But our study has not encountered adverse hepatic effect of stavudine and it may be one of the safest drugs in the ant HIV armamentarium.

Most reports on the hepatic toxicity of nevirapine show that the abnormality of liver function tests are reversible after discontinuation of the drug (Johnson and Baraboutis, 2000; Martinez et al., 2001; Piliro and Purdy, 2001). Present study is the first to show that even on continuation of treatment, by four weeks, hepatic function remarkably improves. Lamivudine normalizes alanine amino transferase levels and reduces hepatic inflammation (Hache and Villeneuve, 2006). A potential criticism of this work may be our failure to assay for alkaline phosphatase (ALP) activity in our model. ALP is a marker enzyme for plasma membrane and endoplasmic retnudum (Wright and Plummer, 1974), but ALAT and ASAT are more specific markers of necrotic injury and cholestasis (Speech and Liehr, 1983; Lott and Wolf, 1986). Hence, ALP being ubiquitous, failure to assay it may not adversely affect or invalidate the conclusions that can be drawn from the study.

The liver being the organ chiefly involved in drug metabolism is endowed with drug metabolizing enzymes for the purpose. Drugs are metabolized through two phases of reactions. In some instances such reactions convert drugs into reactive forms and hence toxicity results.

Drug-induced toxicity is the most frequent reason for the withdrawal of a drug from the market and accounts for more than 50% of cases of acute liver failure in the United States (Reed, 2001). The exact mechanisms by which nevirapine and lamivudine cause adverse hepatic events have not been elucidated, but Lee (2003) reports that drug-induced liver injury occurs via at least 6 mechanisms involving various intracellular organelles, with consequent disruption of intracellular calcium homeostasis, decline in ATP levels and finally hepatocyte swelling and rupture (Beaufre, 1987; Yun et al., 1993). Other cells within the liver may be the target of drug-induced liver damage or modulate incipient reaction. For example, kupffer cells may activate cytokines which may amplify
liver injury or macrophages may augment injury, produce fibrosis or granulomas (Lee, 2003). Decreases in serum total proteins are an indication of hepatotoxicity (Abatan et al., 1996). Increases in activities of ALAT and ASAT directly reflect a major permeability problem or cell rupture (Benjamin, 1978). ASAT exhibits high activity in cytoplasm, mitochondrion and microsomes of liver, heart, kidney and brain (Benjamin, 1978; Ringer et al., 1979). ALAT is hepatocyte-specifically found in the cytosol of hepatocytes. Elevated ALAT levels are associated with acute liver and cholestatic disease (Wolf, 2003). Elevated levels of conjugated bilirubin occur in intrahepatic cholestasis (Wolf, 2003). Defect in metabolism of bilirubin generally reflects defective metabolic capacity of the liver (Schreiber, 2004). As indicated by the results of the three antiretroviral drugs only nevirapine is associated with significant activities of ALAT and ASAT upon both acute and sub-chronic administration. Elevated activities of these enzymes indicate cell damage which might have resulted from several mechanisms, generation of toxic species, peroxidation of membranes et al. Nevirapine and lamivudine perhaps depress protein synthesis as indicated by the decreased levels of total proteins, albumin and globulins.

Nevirapine also impairs the excretory capacity of the liver as shown by the significant increases in levels of total bilirubin. Present results are in agreement with report by Bartlett and Gallant (2003) on the toxicity of nevirapine.

Administration of drugs that are hepatotoxic to HIV/AIDS patients may have untoward consequences. The lives of patients are put at risk. One study reports fatal case resulting from liver failure consequent to nevirapine toxicity (Anonymous, 2000). A damaged liver may fail to metabolize drugs and thus prolong their stay in circulation and cause further toxicity or drugs that need to be metabolized to active forms may not be so converted. There is high chance that a drug may be withdrawn due to its toxicity or the patient may fail to comply with the treatment regimen both of which may adversely affect the outcome of treatment.

We conclude that nevirapine and lamivudine are associated with hepatic adverse events and must be used with caution and close monitoring of liver enzymes may be critical in preventing life threatening events. Inclusion in the treatment regimen of agents which are hepatoprotective should be seriously considered. Further work is on going in our laboratory to assess the specific nature of the hepatic toxicity through histopathological investigations.

REFERENCES


